365 related articles for article (PubMed ID: 29101113)
1. Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise.
Sumanasuriya S; De Bono J
Cold Spring Harb Perspect Med; 2018 Jun; 8(6):. PubMed ID: 29101113
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Prostate Cancer Treatment and Drug Discovery.
Nevedomskaya E; Baumgart SJ; Haendler B
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29734647
[TBL] [Abstract][Full Text] [Related]
3. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
4. Metastatic castration-resistant prostate cancer: time for innovation.
Tucci M; Scagliotti GV; Vignani F
Future Oncol; 2015; 11(1):91-106. PubMed ID: 25572785
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H; Bahl A; Mason M; Troup J; De Bono J
BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
[TBL] [Abstract][Full Text] [Related]
6. Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
Bambury RM; Rathkopf DE
Urol Oncol; 2016 Aug; 34(8):348-55. PubMed ID: 26162486
[TBL] [Abstract][Full Text] [Related]
7. Current approaches to incorporation of radium-223 in clinical practice.
Parker C; Heidenreich A; Nilsson S; Shore N
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):37-47. PubMed ID: 29298991
[TBL] [Abstract][Full Text] [Related]
8. The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
Pagliuca M; Buonerba C; Fizazi K; Di Lorenzo G
Drugs; 2019 Mar; 79(4):381-400. PubMed ID: 30742279
[TBL] [Abstract][Full Text] [Related]
9. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
10. Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer.
Antonarakis ES
Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
[No Abstract] [Full Text] [Related]
11. Sequencing of agents in castration-resistant prostate cancer.
Lorente D; Mateo J; Perez-Lopez R; de Bono JS; Attard G
Lancet Oncol; 2015 Jun; 16(6):e279-92. PubMed ID: 26065613
[TBL] [Abstract][Full Text] [Related]
12. Novel molecular targets for the therapy of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sternberg CN
Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
[TBL] [Abstract][Full Text] [Related]
13. New treatment options for patients with metastatic prostate cancer.
Snoeks LL; Ogilvie AC; van Haarst EP; Siegert CE
Neth J Med; 2013; 71(6):290-4. PubMed ID: 23956309
[TBL] [Abstract][Full Text] [Related]
14. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
15. [Effect and adverse event of enzalutamide and abiraterone in prostate cancer].
Kosaka T; Oya M
Nihon Rinsho; 2015 Feb; 73 Suppl 2():308-12. PubMed ID: 25831773
[No Abstract] [Full Text] [Related]
16. The evolving role of enzalutamide on the treatment of prostate cancer.
Nadal R; Bellmunt J
Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
[TBL] [Abstract][Full Text] [Related]
17. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
[TBL] [Abstract][Full Text] [Related]
18. Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
Maughan BL; Antonarakis ES
Curr Treat Options Oncol; 2015 Dec; 16(12):57. PubMed ID: 26537882
[TBL] [Abstract][Full Text] [Related]
19. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
20. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
Schalken J; Fitzpatrick JM
BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
